FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:627-628 February 10, 2005 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mannon, P. J. PubMed Citation

To the Editor: Mannon et al. (Nov. 11 issue)¹ describe the safety of anti–interleukin-12 antibody (anti–interleukin-12) for the treatment of active Crohn's disease. Among the 44 recipients of anti–interleukin-12 who could be evaluated at 18 weeks, no serious infections were reported.

These results are similar to those of the original studies of infliximab for the treatment of Crohn's disease and rheumatoid arthritis, in which serious infectious complications were not identified.^2,3 The small number of patients enrolled, the exclusion of those at risk, and the limited follow-up for uncommon events are also similar. Through post-marketing surveillance, we learned that anti–tumor necrosis . . . [Full Text of this Article]

This article has been cited by other articles:

• Gaffen, S.L., Hajishengallis, G. (2008). A New Inflammatory Cytokine on the Block: Re-thinking Periodontal Disease and the Th1/Th2 Paradigm in the Context of Th17 Cells and IL-17. JDR 87: 817-828 [Abstract] [Full Text]  
• Keane, J. (2005). TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 44: 714-720 [Abstract] [Full Text]